Group Walden


Research Area

The research of my group is centred on the immunology of skin cancers (melanoma, cutaneous lymphomas, epithelial cancers) and aims at understanding the antigenicity of tumour cells and regulation including the reasons for failure of tumour-specific immune responses. It is patient-based and translational. We employ all available technologies for antigen discovery such as proteome serology and seroscreening of expression libraries for antigens recognised by antibodies, and peptidomics involving extraction, isolation by HPLC and sequencing by mass spectrometry of peptides bound by major histocompatibility (MHC) molecules (HLA) plus sequence screens and bioinformatics to define T cell epitopes. Together with epitope design by molecular library and bioinformatics approaches this is used to develop T cell-directed vaccines. We use multiparameter flow cytometry with up to 14 colours, real-time PCR and toponomics (multiepitope immunohistochemistry with 200 and more specificities) to unravel the immune-regulatory processes in cancer. From these works we can expect information on molecular-pathological processes in cancer as sensed by the immune system, and leads for new strategies and targets for immunotherapy some of which have already been tested in clinical trials.

Selected Publications

Forgber M, Trefzer U, Sterry W, Walden P
Proteome serological determination of tumor-asso-ciated antigens in melanoma.
PLOS One 2009; 4(4):5199.
Hofmann MA, Kors C, Audring H, Walden P, Sterry W, Trefzer U
Phase I Evaluation of Intralesionally-Injected TLR9-Agonist PF-3512676 in Patients With Basal Cell Carcinoma or Metastatic Melanoma.
J of Immunother 2008; 31:520-7.
Losch FO, Bredenbeck A, Hollstein VM, Walden P, Wrede P
Evidence for a large double-cruci-form DNA structure on the X chromosome of human and chim-panzee.
Hum Gen 2007; 122:337-43.
Basu R, Syamal Roy S, Walden P
HLA class I-restricted T cell epitopes of the kmp-11 protein presented by Leishmania donovani-infected human macrophages.
J Inf Dis 2007; 195:1373-80.
Zehn D, Cyril J. Cohen CJ, Yoram Reiter Y, Walden P
Efficiency of peptide presentation by dendritic cells compared to other cell types: Implications for cross-priming.
Int Imm 2006; 18:1647-54.
Bredenbeck A, Losch FO, Sharav T, Eichler-Mertens M, Filter M, Givehchi A, Sterry W, Wrede P, Walden P
Identification of non-canonical melanoma-associated T cell epitopes for cancer immunotherapy.
J Immunol 2005 2005; 174:6716-24.
Demine R, Walden P
Testing the role of gp96 as peptide chaperone in antigen processing.
J Biol Chem 2005; 280:17573-8.
Lev A, Noy R, Oved K, Novak H, Segal D, Walden P, Zehn D, Reiter Y
Tumor-specific Ab-mediated targeting of MHC-peptide complexes induces regression of human tumor xenografts in vivo.
Proc Natl Acad Sci 2004; 101:9051-6.
Zehn D, Cohen CJ, Reiter Y, Walden P
Extended presentation of specific MHC-peptide complexes by mature dendritic cells compared to other types of antigen-presenting cells.
Eur J Immunol 2004; 34:1551-60..
Trefzer U, Herberth G, Wohlan K, Milling A, Thiemann M, Sherev M, Sparbier K, Sterry W, Walden P
Vaccination with hybrids of tumor and dendritic cells induces tumor-specific T cell and clinical responses in melanoma stage III and IV patients.
Int J Cancer 2004; 110:730-40.